Recent studies similarly indicated that CYBB promotes liver tumor formation in nonalcoholic steatohepatitis by inducing oxidative DNA damage.[27] CYBB is a potential biomarker or target for the accurate diagnosis and treatment of gastric cancer.[28] Mutations in the CYBB can lead to reduced NADPH oxidase activity and chronic granulomatous disease.[29] However, the role and mechanisms related to OS in CYBB in PE require further study. The gene discussed is FMO5; the disease is metabolic dysfunction-associated steatohepatitis.